A Phase 1 Clinical Trial of NXP900 in Subjects With Advanced Cancers
Phase 1
140
about 3.8 years
18+
10 sites in AZ, CO, FL +5
What this study is about
Researchers are testing a new treatment, NXP900, for advanced cancers. The trial will start with a small group of people to determine the best dose and then expand to more participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NXP900
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of patients with treatment related adverse events and/or clinical laboratory abnormalities, Part A: Number of patients who experience Dose Limiting Toxicities (DLT) as defined in the protocol, Part B: Disease Control Rate (DCR), Part B: Duration of Response (DoR), Part B: Objective response rate (ORR)
Secondary: Apparent plasma clearance at steady state (Clss/F) of NXP900, Area under the concentration-time curve (AUC) of NXP900, Half-life (T1/2) of NXP900, Maximum observed concentration (Cmax) of NXP900, Time to peak concentration (Tmax) of NXP900
Oncology, Respiratory